secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001714899-23-000119
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q2 net income $183M on Biogen opt-in; discontinues DNL919 in Alzheimer's
-------------------------------------------------------------------------------

- Net income $183.4M (Q2 2022: net loss $58.8M) on $294.1M collaboration revenue from Biogen's ATV:Abeta option.
- Discontinued DNL919 (ATV:TREM2) in Alzheimer's due to narrow therapeutic window and evolving treatment landscape.
- Biogen exercised option to license ATV-amyloid-beta program; will handle development and commercialization.
- Revised BIIB122 (LRRK2) program: focus on LUMA study in Parkinson's; LIGHTHOUSE discontinued, no safety issues.
- Cash and marketable securities $1.19B; DNL310 showed ~40-64% NfL reduction in MPS II, IND cleared for DNL126.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/0001714899-23-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/dnli-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001714899-23-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer